Dr. von Minckwitz on Phase III Results of the APHINITY Trial for Breast Cancer | OncLive

Dr. von Minckwitz on Phase III Results of the APHINITY Trial for Breast Cancer

June 6, 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

<<<

View more from the 2017 ASCO Annual Meeting


x